A new Board of Directors was elected by the General Assembly of the members of PhARMA Innovation Forum (PIF) Greece, held yesterday. The new Board came together earlier today for the first time to assign internal roles and responsibilities.
As a result of this procedure, Labrina Barmpetaki, President & Managing Director, Abbvie Pharmaceuticals Greece, Cyprus & Malta was named as the new President of the BoD. Christian Rodseth, Managing Director – Greece, Cyprus, Malta, Poland & Romania at Janssen was appointed as Vice President of the BoD, while Savas Charalampidis, General Manager at Gilead Sciences will be General Secretary of the BoD and Ezat Azem, CEO and President at Roche Hellas will be the Treasurer of the BoD Agata Jakoncic, CEO at MSD for Greece, Cyprus & Malta, Yvoni Papastelatou, Sanofi Country Lead Greece & Cyprus & General Manager Specialty Care Greece & Cyprus and Elena Chouliara, President & Managing Director at AstraZeneca Greece & Cyprus will be members of the BoD.
The first part of the General Assembly, in which all 26 member companies of PhARMA Innovation Forum Greece participated, was dedicated to the report on the work of the outgoing Board during the previous three years. Then followed the election process, from which the new Board of Directors emerged. The new BoD includes four new people, while 3 members remain from the previous board.
We welcome the new Board of Directors and wish them every success in their work and in the continued pursuit of our permanent goal of promoting faster and wider access of patients to innovative treatments in Greece.
PhARMA Innovation Forum Greece
Marieangela Economopoulou
General Manager
